IL6 and congenital rubella syndrome: Pre-emptive mitigation with tocilizumab and corticosteroids is also being explored for CRS and ICANS; the IL-6 inhibitor siltuximab and the IL-1 inhibitor anakinra are under active investigation (however, at present the availability of siltuximab is variable) (25).